<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280902</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/25</org_study_id>
    <nct_id>NCT02280902</nct_id>
  </id_info>
  <brief_title>Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases</brief_title>
  <acronym>INFIM</acronym>
  <official_title>Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections represent the first cause of death and of morbidity in people treated for
      immunologic and inflammatory diseases with corticosteroids, immunosuppressive drugs or
      biotherapy. Epidemiological, clinical, biological and therapeutic determinants of these
      infections are poorly understood. There is no recommendation for the prevention and treatment
      of infections in this particular field.

      Purpose : Recent therapeutic trials evaluating immunosuppressive and biotherapy
      (cyclophosphamide, mycophenolate mofetil, rituximab, belimumab) in the field of immunologic
      and inflammatory diseases have found a risk of severe infection of 7 to 18% during the first
      year after the beginning of the treatment. Thus, the main objective of the study is to
      describe the incidence and risk-factors for infections in people treated with such agents for
      immunologic and inflammatory diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monitoring of neutrophils, lymphocytes, immune activation markers, immunoglobulins have not
      been prospectively studied in such patients. Preliminary retrospective studies have shown
      that total lymphopenia was independently associated with an increased risk of infections. A
      previous retrospective study from our group have also shown that total lymphopenia and CD3-
      lymphopenia three months after the beginning of rituximab was associated with infections.

      The determinants of infections occurring during the course of immune and inflammatory
      diseases treated with corticoids and immunosuppressive drugs or biotherapy are probably
      multiples. We hypothesized that the following variables may have an impact on the risk of
      infections in those patients: Epidemiological: gender, social situation, Clinical: causal
      disease, comorbidities, vaccination status, Therapeutic: type and doses of corticosteroids
      and immunosuppressive drugs/biotherapy, prevention treatment Biological : neutrophils, total
      lymphocytes, CD4-T lymphocytes, CD8-T lymphocytes, B lymphocytes, immune activation (HLA-DR+
      lymphocytes), CD5 and CD19 lymphocytes, CD27/IgD lymphocytes, immunoglobulins IgA, IgM, IgG.

      On the other side, the impact of infection on the clinical course of immunologic or
      inflammatory disease have been poorly described and will be documented by this longitudinal
      study.

      After inclusion in the present study, patients will be followed on a 30 months period and
      monitored at M3, M6, M12, M24 to describe the impact of treatment on clinical and biological
      variables. Every clinical event will be prospectively reported and validated by a specific
      committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Viral, bacterila, fungal or parasitic infection leading to hospitalization</measure>
    <time_frame>30 months after the inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological and immunological markers</measure>
    <time_frame>Each 6 months from baseline for 30 months</time_frame>
    <description>The following items will be assessed every 6 months :
total White blood cell CD3 CD4 CD8 HLA-DR+ B cells CD19+ B cells CD5+/- CD27/IgD NK cells IgA, IgM, IgG levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Each 6 months from baseline for 30 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">217</enrollment>
  <condition>Immunologic and Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>Patient with immunologic and inflammatory diseases</arm_group_label>
    <description>Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.</description>
    <arm_group_label>Patient with immunologic and inflammatory diseases</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      - Blood sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic
        and inflammatory diseases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Immune or inflammatory disease : Lupus, antiphospholipid syndrome, Sjogren syndrome,
             inflammatory myositis, immunologic thrombopenic purpura, autoimmune hemolytic anemia,
             Evan's syndrome, systemic vasculitis, Behcet disease.

          -  Indication of corticosteroid therapy &gt; 20 mg for at least 3 months and/or
             immunosuppressive or biologic agent.

          -  Information consent

        Exclusion Criteria:

          -  Previous treatment with immunosuppressive or biological agents, or cumulative dose of
             steroids &gt; 1g last 6 months

          -  Splenectomy

          -  Pregnancy

          -  Evoluting Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice BONNET, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodolphe THIEBAUT, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice BONNET, Prof.</last_name>
    <phone>(0) 556795826</phone>
    <phone_ext>+33</phone_ext>
    <email>fabrice.bonnet@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Médecine Interne - CH d'Agen</name>
      <address>
        <city>Agen</city>
        <zip>47923</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick RISPAL, MD</last_name>
      <email>patrick.rispal@ch-agen.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick RISPAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne et maladies Infectieuses - Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BONNET, Prof.</last_name>
      <phone>(0)5 56 79 58 26</phone>
      <phone_ext>+33</phone_ext>
      <email>fabrice.bonnet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice BONNET, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Partick MERCIE, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien SENESCHAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre MERVILLE, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe RICHEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne - CH de Libourne</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier CAUBET, MD</last_name>
      <email>olivier.caubet@ch-libourne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume GONDRAN, MD</last_name>
      <email>guillaume.gondran@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaune GONDRAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - CH de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier DELBREL, MD</last_name>
      <email>xavier.delbrel@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DELBREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service Médecine Interne - CHU de Toulouse - Hôpital Purpan (5)</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent SAILLER, Prof.</last_name>
      <email>sailler.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent SAILLER, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service Médecine Interne - CHU de Toulouse - Hôpital Purpan (7)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent ALRIC, Prof</last_name>
      <email>alric.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>auto-immune diseases</keyword>
  <keyword>inflammatory diseases</keyword>
  <keyword>risk factors</keyword>
  <keyword>infections</keyword>
  <keyword>cohort study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

